Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for High-Risk Intrahepatic Cholangiocarcinoma
NCT04546828Phase 2Withdrawn
- Sponsor
- Samsung Medical Center
- Start
- Feb 2021
- Primary completion
- Aug 2021
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of paclitaxel in intrahepatic cholangiocarcinoma (ICC), sponsored by Samsung Medical Center. Planned start Feb 2021; status: withdrawn.
02
Drugs
paclitaxel
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT04546828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04546828.